Product Program year 2020 Source: CMS Open Payments

Evis Exera

Device GI & Respiratory Products

Open in the dashboard

General payments

$2,043,215

1,295 payments

Research payments

$1,678,340

13 payments

Through program year 2020, $2,043,215 in general payments and $1,678,340 in research payments were reported against Evis Exera (GI & Respiratory Products).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Amount Payments
2020 General $725,862 598
2020 Research $21,064 3
2019 General $1,317,353 697
2019 Research $1,657,276 10

Breakdown

Who paid General payments · program years 2019–2020
  1. Olympus Corporation of the Americas $1,167,226 1,032 payments
  2. Olympus America Inc. $825,004 222 payments
  3. Olympus Latin America, Inc. $29,820 32 payments
  4. Olympus Corporation $21,165 9 payments
Top recipients General payments · program year 2020
  1. Mount Sinai Hospital Teaching hospital · NY $285,856 39% · 2 payments
  2. Cedars-Sinai Medical Center Teaching hospital · CA $78,800 11% · 1 payment
  3. Ut Md Anderson Cancer Center Teaching hospital · TX $69,001 10% · 1 payment
  4. Faxton-St. Lukes Healthcare Teaching hospital · NY $39,750 5% · 1 payment
  5. The Queens Medical Center Teaching hospital · HI $23,542 3% · 3 payments

The top 5 of 96 recipients; each share is of general payments naming this product in 2020.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2020
  1. Gastroenterology Internal Medicine $187,638 99% · 75 practitioners
  2. Pulmonary Disease Internal Medicine $1,320 <1% · 1 practitioner
  3. Internal Medicine $1,238 <1% · 3 practitioners

Each share is of general payments naming this product to practitioners with a specialty in 2020. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2020
  1. New York $367,355 51% · 8 recipients
  2. California $106,851 15% · 10 recipients
  3. Texas $81,947 11% · 6 recipients
  4. Florida $47,294 7% · 14 recipients
  5. Washington $27,016 4% · 3 recipients

The top 5 of 28 states; each share is of general payments naming this product in 2020 where a state was reported.

The top 25 states, free in the app

1,295 general · 13 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2020

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record